Graft-versus-host disease in allogeneic bone marrow transplantation: The role of monoclonal antibodies in prevention and treatment

British Journal of Biomedical Science

Volumn 57, Issue 2, 2000, Pages 163-169

  Hiscott, A ^a   McLellan, D S ^b  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b UNIVERSITY OF PORTSMOUTH   (United Kingdom)

Author keywords

Antibodies, monoclonal; Bone marrow transplantation; Graft vs host disease

Indexed keywords

CYCLOSPORIN A; CYTOKINE; METHOTREXATE; MONOCLONAL ANTIBODY; OKT 3; PREDNISOLONE; STEROID; THALIDOMIDE; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ALLOGENIC BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; GASTROINTESTINAL DISEASE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKEMIA; LIVER DISEASE; LYMPHOPROLIFERATIVE DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SKIN DISEASE; T LYMPHOCYTE;

ANTIBODIES, MONOCLONAL; BONE MARROW TRANSPLANTATION; GRAFT VS HOST DISEASE; HUMANS;

EID: 0034083757     PISSN: 09674845     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Mathe G, Jammet H, Pendic B et al. Transfusions et greffes de moelle osseuse homologue chez des humains irradies a hautes dose accidentellement. Rev Fr Etudes Clin Bio 1959; 4:226-38.
2. Hoffbrand AV, Pettit JE. Essential Haematology, 3rd Edition. Oxford: Blackwell Science, 1995:130-1.
3. Billingham RE. The biology of graft-versus-host reactions. Harvey Lectures 1996; 62:21-79.
4. Bron D. Graft versus host disease. Curr Opin Oncol 1994; 6:358-64.
5. Grigg A, Morton J, Durrant S. Factors influencing the outcome of donor marrow transplantation in adults from less than ideal donors: experience from two Australian centres. Aust NZ J Med 1997; 27:311-8.
6. Chown SR, Marks DI, Cornish JM et al. Unrelated donor bone marrow transplantation in children and young adults with acute myeloid leukaemia in remission. Br J Haematol 1997; 99:36-40.
7. Oakhill A, Pamphillon DH, Potter MN et al. Unrelated donor bone marrow transplantation for children with relapsed acute lymphoblastic leukaemia in second complete remission. Br J Haematol 1996; 94:574-8.
8. Storb R, Deeg HJ, Pepe M et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukaemia: long term follow-up of a controlled trial. Blood 1989; 73:1729-34.
9. Herve P, Wijdenes J, Bergerat JP et al. Treatment of cortico-steroid-resistant acute graft-versus-host disease by in vivo administration of anti-interleukin-2 receptor monoclonal antibody (B-B10). Blood 1990; 75:1017-23.
10. Hale G, Waldmann H. Control of graft-versus-host disease and graft rejection by T-cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplant for malignant diseases. Bone Marrow Transplant 1994; 13:597-611.
11. Aschan J, Ringden O, Sundeberg B et al. Increased risk of relapse in patients with chronic myelogenous leukaemia given T-cell depleted marrow compared to methotrexate combined with cyclosporin or monotherapy for the prevention of graft-versus-host disease. Eur J Haematol 1993; 50:269-74.
12. Varadi G, Or R, Slavin S, Nagler A. In vivo Campath-1 monoclonal antibodies: a novel mode of therapy for acute graft-versus-host disease. Am J Haematol 1996; 52:236-7.
13. Goldstein G, Schindler J, Tsai H et al. A randomised clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 1985; 313:317-42.
14. Anasetti C, Martin PJ, Strob R et al. Treatment of acute graft-versus-host disease with a non-mitogenic anti-CD3 monoclonal antibody. Transplantation 1992; 54:844-51.
15. Hale G, Clark MR, Marcus R et al. Remission induction in non-Hodgkin's lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 1988; 2:1394-9.
16. Tsukazaki K, Kuroda K, Mochizuki K et al. A human monoclonal antibody to carbohydrate moiety of carcinoembryonic antigen. Hum Antibod Hybrid 1995; 6:145-52.
17. Kernan NA, Byers V, Scannon PJ et al. Treatment of steroid-resistant acute graft-versus-host disease by in vivo administration of an anti-T-cell ricin A chain immunotoxin. JAMA 1988; 259:3154-7.
18. Kreitman RJ, Pastan I. Recombinant single-chain immunotoxins against T-and B-cell leukaemias. Leuk Lymphoma 1994; 13:1-10.
19. 486IL-2) in haematologic malignancies: complete response in a patient with Hodgkin's disease refractory to chemotherapy. Cancer 1994; 73:1276-85.
20. Choa NJ, Schlegel PG. Prevention and treatment of graft-versus-host disease. Ann NY Acad Sci 1995; 770:130-40.
21. Guinan EC, Gribben JG, Boussiotis VA et al. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood 1994; 84:3261-82.
22. Vogeslang GB, Morris LE. Prevention and management of graft-versus-host disease. Drugs 1993; 45:668-76.
23. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18:295-304.
24. Thomas ED, Storb R, Clift RA et al. Bone marrow transplantation. N Engl J Med 1975; 292:895-902.
25. Gratwohl A, Hermans J, Apperley J et al. Acute graft-versus-host disease: grade and outcome in patients with chronic myelogenous leukaemia. Blood 1995; 86:813-8.
26. Thomas ED, Storb R, Clift RA et al. Bone marrow transplantation. N Engl J Med 1975; 292:832-43.
27. Sakuma H, Kikuta A, Suzuki H. Treatment of GvHD after blood transfusion. Fukushima J Med Sci 1993; 39:113-6.
28. Passweg JR, Socie G, Hinterberger W et al. Bone marrow transplantation for severe aplastic anemia: has outcome improved? Blood 1997; 90:858-64.
29. Groth CG, Gahrton G, Lundgren G et al. Successful treatment with prednisolone of GvHD in an allogeneic bone marrow transplant recipient. Scand J Haematol 1979; 22:333-8.
30. Weiden PL, Doney K, Storb R, Thomas ED. Anti-human thymocyte globulin (ATG) for prophylaxis and treatment of graft-versus-host disease in recipients of allogeneic marrow grafts. Transplant Proc 1978; 10:213-6.
31. Deeg HJ, Loughton Jr TP, Storb R et al. Treatment of human acute graft-versus-host disease with antithymocyte globulin and cyclosporin with or without methylprednisolone. Transplantation 1985; 40:162-6.
32. Vogelsang GB, Santos GW, Colvin OM, Chen T. Thalidomide for graft-versus-host disease. Lancet 1988; 1:827.
33. Sullivan KM, Witherspoon RP, Storb R et al. Alternating-day cyclosporin and prednisolone for treatment of high-risk chronic GvHD. Blood 1988; 72:555-61.
34. Hale G, Xia M-Q Tighe HP et al. The Campath-1 antigen (CDw52). Tissue Antigens 1990; 35:118-27.
35. Knullst AC, Tibbe GJM, Noort WA et al. Prevention of lethal graft-versus-host disease in mice by monoclonal antibodies directed against T-cells or their subsets. I. Evidence for the induction of a state of tolerance based on suppression. Bone Marrow Transplant 1994; 13:293-301.
36. Li J, Helm K, Howell CD. Contributions of donor CD4 and CD8 cells to liver injury during murine graft-versus-host disease. Transplantation 1996; 62:1621-8.
37. Cohen J. Cytokines as mediators of graft-versus-host disease. Bone Marrow Transplant 1988; 3:193-7.
38. Tong J, Viale M, Bacigalupo A et al. Cytokine serum levels and acute graft-versus-host disease after allogeneic bone marrow transplantations. Haematologica 1992; 77:365-6.
39. Holler E, Kolb HJ, Hintermeier-Knabe R et al. Role of tumor necrosis factor alpha in acute graft-versus-host disease and complications following allogeneic bone marrow transplantation. Transplant Proc 1993; 25:1234-6.
40. Holler E, Kolb HJ, Wilmanns W et al. Treatment of graft-versus-host disease, TNF alpha antibodies and related antagonists. Bone Marrow Transplant 1993; 12:529-31.
41. Gluckman E, Devergie A, Varin F et al. Treatment of steroid-resistant severe acute graft-versus-host disease with a monoclonal pan-T OKT3 antibody. Exp Haematol 1984; 12:66-7.
42. Martin PJ, Hansen JA, Anasetti C et al. Treatment of acute graft-versus-hose disease with anti-CD3 monoclonal antibodies. Am J Kidney Dis 1988; 11:149-52.
43. Filipovich AH, Kraxczak CL, Kersey JH et al. Graft-versus-host disease prophylaxis with anti T-cell monoclonal antibody OKT3, prednisolone and methotrexate in allogeneic bone marrow transplantation. Br J Haematol 1985; 60:143-52.
44. Anasetti C, Martin PJ, Hansen AJ et al. A phase I-II study evaluating the murine anti-IL-2 receptor antibody 2A3 for treatment of acute graft-versus-host disease. Transplantation 1990; 50:49-54.
45. Cahn JY, Bordigoni P, Tiberghien P et al. Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporin with or without an interleukin-2-receptor monoclonal antibody. Transplantation 1995; 60:939-42.
46. Racadot E, Milpied N, Bordigoni P et al. Sequential use of three monoclonal antibodies in corticosteroid-resistant graft-versus-host disease: a multicentre pilot study including 15 patients. Bone Marrow Transplant 1995; 15:669-77.
47. Waldmann H, Hale G, Cividalli G et al. Elimination of graft-versus-host disease by in vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (Campath-1). Lancet 1984; 2:483-6.
48. Hale G, Clark M, Waldmann H. Therapeutic potential of rat monoclonal antibodies: isotype specificity of antibody-dependent cell-mediated cytotoxicity with human lymphocytes. J Immunol 1985; 134:3056-61.
49. Goldmann JM, Gale RP, Horowitz MM et al. Bone marrow transplantation for chronic myelogenous leukaemia in chronic phase. Ann Int Med 1988; 108:806-14.
50. Hamblin M, Marsh JCW, Lawler M et al. Campath 1G in vivo confers a low incidence of graft-versus-host disease associated with a high incidence of mixed chimaerism after bone marrow transplantation for severe aplastic anaemia using HLA-identical sibling donors. Bone Marrow Transplant 1996; 17:819-24.
51. Naparstek E, Or R, Nagler A et al. T-cell depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse. Br J Haematol 1995; 89:506-15.
52. Byers VS, Henslee JP, Kernan NA et al. Use of an anti-pan-T-lymphocyte ricin-A-chain immunotoxin in steroid-resistant acute graft-versus-host disease. Blood 1990; 75:1426-32.
53. Martin PJ, Nelson BJ, Appelbaum FR et al. Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Blood 1996; 88:824-30.
54. Byers VS, Baldwin RW. Rationale for clinical use of immunotoxins in cancer and autoimmune disease. Semin Cell Biol 1991; 2:59-70.
55. Deutsch VR, Nagler A, Slavin S et al. Effect of bone marrow T-lymphocytes treated with Campath 1G on megakaryocyte colony formation. Exp Haematol 1993; 21:1427-35.
56. Ringden O, Hermans J, Labopin M et al. The highest leukaemia-free survival after allogeneic bone marrow transplantation is seen in patients with grade I acute graft-versus-host disease. Leuk Lymphoma 1996; 24:71-9.
57. Byers VS, Baldwin RW. Therapeutic strategies with monoclonal antibodies and immunoconjugates. Immunology 1988; 65:329-35.
58. Drobyski WR, Majewski D. Treatment of donor mice with an αβ T-cell receptor monoclonal antibody induces prolonged non-responsiveness and effectively prevents graft-versus-host disease in murine recipients of major histocompatibility complex (MHC)-matched and MHC-mismatched donor marrow grafts. Blood 1996; 87:5355-69.
59. Williamson E, Garside P, Bradley A et al. Neutralizing IL-12 during induction of murine acute graft-versus-host disease polarizes the cytokine profile toward a Th2-type alloimmune response and confers long-term protection from disease. J Immunol 1997; 159:1208-15.
60. Goldman J. Peripheral blood stem cells for allografting. Blood 1995; 85:1413-5.